Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Sep 5;144(10):1029-1031.
doi: 10.1182/blood.2024025237.

A fresh look at covalent BTK inhibitor resistance

Lindsey E Roeker  1
Affiliations
Editorial

A fresh look at covalent BTK inhibitor resistance

Lindsey E Roeker. Blood. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: L.E.R. has served as a consultant for AbbVie, Ascentage, AstraZeneca, Beigene, Janssen, Loxo Oncology, Pharmacyclics, Pfizer, TG Therapeutics; is a member of a data safety monitoring committee for Ascentage; served as a Continuing Medical Education speaker for DAVA, Curio, Medscape, and PeerView; holds minority ownership interest in Abbott Laboratories; received travel support from Loxo Oncology; and has received research funding (paid to the institution) from Adaptive Biotechnologies, AstraZeneca, Genentech, AbbVie, Pfizer, Loxo Oncology, Aptose Biosciences, Dren Bio, and Qilu Puget Sound Biotherapeutics.

Figures

None
In this study, mutational profiling was performed on paired samples from patients with relapsed or refractory CLL who were treated with covalent BTKis (ibrutinib or acalabrutinib) in the ELEVATE-RR study. Here we can see the distribution of BTK and B-cell receptor pathway mutations that developed during treatment with ibrutinib or acalabrutinib.
See this image and copyright information in PMC

Comment on

References

    1. Woyach JA, Jones D, Jurczak W, et al. Mutational profile in previously treated patients with chronic lymphocytic leukemia progression on acalabrutinib or ibrutinib. Blood. 2024;144(10):1061–1068. - PubMed
    1. Woyach JA, Furman RR, Liu T-M, et al. Resistance mechanisms for the Bruton’s tyrosine kinase inhibitor ibrutinib. N Engl J Med. 2014;370(24):2286–2294. - PMC - PubMed
    1. Woyach JA, Ruppert AS, Guinn D, et al. BTKC481S-mediated resistance to ibrutinib in chronic lymphocytic leukemia. J Clin Oncol. 2017;35(13):1437–1443. - PMC - PubMed
    1. Ahn IE, Underbayev C, Albitar A, et al. Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia. Blood. 2017;129(11):1469–1479. - PMC - PubMed
    1. Mato AR, Woyach JA, Brown JR, et al. Pirtobrutinib after a covalent BTK inhibitor in chronic lymphocytic leukemia. N Engl J Med. 2023;389(1):33–44. - PubMed

MeSH terms